On March 21, 2017 Oxis International Inc. (OTCQB: OXIS) (Euronext Paris OXI.PA) reported that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its wholly owned subsidiary, Oxis Biotech Inc., has been invited to speak at the 15th National Conference of Tumor Immunotherapy on June 22, 2017, in Hefei, China (Press release, OXIS International, MAR 21, 2017, View Source [SID1234539556]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Vallera, Director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he will discuss two immunotherapy cancer treatments that he helped develop — Trispecific Killer Engager (TriKE) and Bispecific Killer Engager (BiKE). Both platforms have been licensed by Oxis.
The treatments empower the body’s immune system to identify and selectively kill cancer cells, while leaving healthy cells alone.
Dr. Vallera was instrumental in the development of Oxis’ promising cancer therapy, OXS-1550, which is currently in an FDA Phase 1/Phase 2 clinical trial in Minnesota.
The National Conference of Tumor Immunotherapy focuses on research, technology, clinical practice and government policy related to tumor immunology and immunotherapy. About 500 people are expected to attend.
Anthony Cataldo, Chairman and Chief Executive Officer of Oxis, said Dr. Vallera’s invitation is an indication that his work is widely recognized by his peers.
"We have received many requests for more information about the BiKE and TriKE platforms we have licensed from the University Of Minnesota," Mr. Cataldo said. "The biotech community realizes the potential for this technology and how it addresses the future of ‘Targeted Immunotherapy.’"
Dr. Vallera has spent 35 years with the University of Minnesota’s cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.